AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript

The investable story is not the quarter itself; it is whether the company can convert higher-margin procedural mix into durable operating leverage before the market gets impatient with reinvestment. The mix shift improves the quality of revenue, but management is still choosing to spend heavily on clinical evidence and field expansion, so the P&L re-rate is likely to lag the top-line narrative by several quarters. In other words: fundamental momentum is real, but the near-term multiple expansion is capped until investors see that disposal/probe pull-through is persistent rather than just a reimbursement pop.

The weakest leg is thrombectomy. Competitive intensity there is more likely to show up as lumpy procedure timing and slower account conversion than as overt pricing pressure, which means headline growth can wobble even if the franchise is intact. That creates a second-order read-through to peers: the broader category should continue to expand, but winners will be the names with the best clinical workflow and sales execution, not necessarily the best device alone.

Contrarian view: the market may be over-fixated on capital sales and underweighting the recurring disposable engine. If reimbursement broadens across more MACs, the value of NanoKnife becomes much more like a consumables platform than a hardware story. The thesis breaks if disposable growth stalls after the reimbursement cycle, or if gross margin cannot hold the 54-55% band despite mix tailwind; that would tell you the operating model is not scaling fast enough to justify a higher multiple.